The Week: AI, GLP-1s, and Scott's Iran War Reversal

What It Covers

Scott Galloway's Prof G Pod examines three converging stories from June 2025: mounting evidence that AI costs are outpacing ROI for major corporations, Eli Lilly CEO David Ricks making the case for GLP-1 drugs as a systemic health solution, and Scott publicly reversing his earlier support for U.S. military action in Iran.

Key Questions Answered

• •AI Cost Ceiling: Corporate AI adoption is hitting a financial wall. Uber exhausted its entire 2026 AI budget in four months, Microsoft canceled Claude code licenses company-wide, and an Nvidia executive confirmed compute costs now exceed employee costs. An MIT study found only 5% of AI token usage connects to measurable CFO-level returns, signaling a potential 1999-style reckoning.
• •AI Valuation Risk: SpaceX, OpenAI, and Anthropic are collectively targeting a $4 trillion combined valuation in upcoming IPOs. Scott's explicit recommendation for anyone holding pre-IPO shares in these companies: sell before Monday. The parallel drawn is to dot-com era hype, where narrative outpaced fundamentals until the market corrected sharply in 2000.
• •GLP-1 Systemic Impact: Eli Lilly CEO David Ricks identifies two properties that make GLP-1 drugs like Zepbound structurally different from most pharmaceuticals: near-universal efficacy across patients and positive subjective experience during use. Because obesity connects to over 200 chronic diseases, widespread GLP-1 access could materially shift U.S. life expectancy if distribution channels are reformed.
• •Healthcare Structural Failure: U.S. healthcare spending reached $5.3 trillion in 2024, over $15,000 per person and nearly one-fifth of GDP, yet produces shorter lifespans than comparable wealthy nations. Hospital pricing consolidation, not insurer behavior, is identified as the primary cost driver. By 2033, one in every five dollars in the U.S. economy will flow to healthcare.
• •Anxiety Management Framework: Dan Harris's principle "action absorbs anxiety" offers a concrete behavioral tool: when facing health concerns, job searches, or financial stress, initiating a specific physical step — booking a doctor's appointment, drafting a resume — reduces anxiety neurologically before the problem is resolved. The act of moving toward a problem, not solving it, is the mechanism.